Results 121 to 130 of about 22,351 (243)

Fingolimod w leczeniu stwardnienia rozsianego

, 2010
W chwili obecnej leczenie immunomodulujące stwardnienia rozsianego (łac. sclerosis multiplex, SM) polega na podawaniu leków w postaci iniekcji podskórnych, domięśniowych bądź dożylnych.
Andrzej Głąbiński, Paweł Gierach, Marek Juszczak   +2 more
core  

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

Multiple Sclerosis and Related Disorders, 2020
Highlights • First case report of coronavirus disease 2019 (COVID-19) in a multiple sclerosis patient under fingolimod treatment.• The patient revealed severe bilateral interstitial pneumonia on chest CT scan, but recovered rapidly.• It is important to ...
C. Foerch, Lucie Friedauer, B. Bauer, T. Wolf, E. Adam   +4 more
semanticscholar   +1 more source

Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1249-1257, June 2026.
ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt, Marius Ygonia, Ali Manouchehrinia, Philippe Lefrançois, Ingrid Kockum, Adil Harroud   +5 more
wiley   +1 more source

Panzytopenie durch Fingolimod: Hypothese eines neuen Mechanismus

, 2019
Der Wirkstoff Fingolimod ist in Deutschland als krankheitsmodifizierende Monotherapie von hochaktiver schubförmig-remittierend verlaufender Multipler Sklerose bei bestimmten Patienten zugelassen.
Held, T., Hichert, V.
core   +1 more source

Discovery of an Adaptive Neuroimmune Response Driving Itch and Fast Tick Removal with Implications for Preventing Pathogen Transmission

Advanced Science, Volume 13, Issue 32, 9 June 2026.
Itch‐induced tick removal (IITR): An acquired neuroimmune mechanism, itch‐induced tick removal, develops after repeated tick exposure, mobilizing T cells and macrophages at the tick bite site to trigger a rapid scratching response that facilitates timely tick removal within a critical window that precedes the transmission of many tick‐borne pathogens ...
Johannes S. P. Doehl, Tiago D. Serafim, Serena Doh, Charles S. Grugan, Eva Iniguez, Luana Rogerio, Ronja Frigard, Ranadhir Dey, Pedro Cecilio, Xinglong Gu, Pang‐Yen Tseng, Aline da Silva Moreira, Mahnaz Minai, James Oristian, Hans Ackerman, Steven Brooks, Caroline Percopo, Siu‐Ping Ng, Derron A. Alves, Lucas Tirloni, Jennifer M. Anderson, Adriana Marques, Fabiano Oliveira, Shaden Kamhawi, Daniel E. Sonenshine, José M. C. Ribeiro, Mark Hoon, Jesus G. Valenzuela   +27 more
wiley   +1 more source

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis

, 2015
Alberto Gajofatto,1,2 Marco Turatti,2 Salvatore Monaco,1,2 Maria Donata Benedetti2 1Department of Neurological, Biomedical and Movement Sciences, University of Verona, Verona, Italy; 2Division of Neurology B, Verona University Hospital, Verona, 
Gajofatto A, Turatti M, Monaco S, Benedetti MD   +3 more
core  

A Comprehensive Disproportionality Analysis of Drug‐Related Head Injury Reports Using the FAERS Database

Brain and Behavior, Volume 16, Issue 6, June 2026.
ABSTRACT Objective This study aimed to identify and characterize drugs associated with reports of head injury through a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database. Methods A retrospective disproportionality analysis was conducted on FAERS reports from 2004 to 2023.
Jiaqi Guo, Luming Wei, Junfeng Liu, Jimei Zhang, He Wang, Wanjun Lu   +5 more
wiley   +1 more source

Disseminated Cryptococcosis under Fingolimod Therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler, Morna F. Schmidt, Ana Ortins‐Pina, David Kluwig, Amir S. Yazdi   +4 more
wiley   +1 more source

When Treatment Turns to Stone: Injection‐Site Calcinosis Associated With Interferon‐β in Multiple Sclerosis: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Injection‐site calcinosis is a rare complication of interferon‐β therapy in multiple sclerosis. We report a 52‐year‐old woman with stable bilateral gluteal calcifications after long‐term subcutaneous interferon‐β‐1b therapy. Findings were most consistent with probable dystrophic calcinosis cutis secondary to chronic repeated injection‐site ...
Anna Walter, Adam Bott, Marianne Kiechle, Margret Hund‐Georgiadis   +3 more
wiley   +1 more source

Investigation of the Effects of Fingolimod on the LPS-Induced Inflammatory Response in the HUVEC Cell Line

Pharmata
Aim: The objective of this study was to examine the impact of fingolimod on tumour necrosis factor-alpha (TNF-α) production in the context of a lipopolysaccharide (LPS)-induced inflammatory response in a human umbilical vein endothelial cells (HUVEC ...
Hamza Halıcı, Eda Yilmaz
doaj   +1 more source